Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of MEDI-570 in Relapsed/Refractory T-Cell Lymphomas
NCT02520791Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2016
- Primary completion
- Dec 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of MEDI-570 in peripheral T-cell lymphoma (PTCL), angioimmunoblastic T-cell lymphoma (AITL), follicular lymphoma (FL) and 2 more, sponsored by National Cancer Institute. Primary endpoints: Incidence of toxicity and safety of MEDI-570, Maximum tolerated dose at 21 days and 1 more. Started Sep 2016; status: active, not recruiting.
02
Drugs
MEDI-570
03
Conditions
peripheral T-cell lymphoma (PTCL)angioimmunoblastic T-cell lymphoma (AITL)follicular lymphoma (FL)mycosis fungoides (MF)cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT02520791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02520791.